Is HELP a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for HELP (HELP) rests on Phase 3 depression readout: The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. Revenue (TTM) is ~$0 (pre-revenue, under $1M). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. Whether HELP is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based clinical-stage pharmaceutical company. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog being studied as an adjunctive treatment for major depressive disorder in a pivotal Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting. As a pre-revenue biotech, Cybin has essentially no product sales and reports widening net losses as it funds late-stage trials. The company reported cash of roughly $195 million at the end of 2025, giving it a runway measured in quarters rather than years, and it has repeatedly raised equity to extend that runway. The investment picture is therefore binary and event-driven: positive Phase 3 topline data (expected around late 2026) and a clear regulatory path could re-rate the stock sharply, while a trial miss, a financing gap, or heavy dilution could impair it. This is a high-risk, high-variance profile typical of psychedelic-medicine developers.
What's the case for buying HELP?
1. Phase 3 depression readout
The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. A clean efficacy and safety result would be the most material value driver, since MDD is a large addressable market and few psychedelic therapies have reached pivotal-stage data.
2. Anxiety program optionality
HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder with an earlier data readout expected around Q1 2026. Positive signals here would broaden the pipeline beyond a single depression bet and give the platform a second indication.
3. Cash position and financing
Cybin ended 2025 with roughly $195 million in cash, which funds its late-stage trials but implies continued reliance on capital markets. The pace of spending versus milestone timing shapes how much additional dilution shareholders may face before any potential approval.
4. Psychedelic-medicine regulatory path
The broader environment for FDA review of psychedelic and serotonergic therapies is still developing. Clearer agency guidance and precedent from peers could de-risk the category, while setbacks at competing programs could weigh on sentiment across the space.
What are the risks to HELP?
As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points.
How is HELP valued? (as of July 2026)
Snapshot for HELP as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Share price: ~$5
- Market cap: ~$257M
- Revenue (TTM): ~$0 (pre-revenue, under $1M)
- Cash: ~$195M (end of 2025)
- Net loss (annual): widening, roughly $120M+ cash used
- Shares outstanding: ~50M
Standard earnings multiples do not apply because Cybin has essentially no revenue and runs at a loss while funding Phase 3 trials. Much of its roughly $257 million market value is backed by its cash balance of around $195 million, so the market is assigning only a modest premium for the pipeline ahead of pivotal data. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.
How do you decide if HELP is a buy?
Rather than asking whether HELP is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HELP indirectly through an index or sector ETF before adding more.
For the full picture, see the HELP stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HELP against your real portfolio and see your actual exposure before deciding.
The bottom line on HELP
The bottom line: HELP's story right now is Phase 3 depression readout, with revenue (ttm) at ~$0 (pre-revenue, under $1M). If you believe that narrative continues, the call is about sizing HELP sensibly and checking overlap with what you own; if you doubt it (the risk: as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around HELP with Walnut
Use HELP as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is HELP a good stock to buy right now?
+
The case for HELP right now is Phase 3 depression readout, with revenue (ttm) at ~$0 (pre-revenue, under $1M). If you believe that thesis holds, HELP is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is as a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does HELP do?
+
Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based
What are the main risks of HELP?
+
As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points.
What company is the ticker HELP?
+
HELP is Cybin Inc., a clinical-stage biotech that now operates under the name Helus Pharma. It moved its U.S. listing to the Nasdaq under HELP in early 2026 after previously trading as CYBN on NYSE American.
What does Helus Pharma do?
+
It develops psychedelic-derived neuroactive compounds, including a deuterated psilocybin analog and a deuterated DMT analog, designed as supervised therapies for major depressive disorder and generalized anxiety disorder.
Does HELP have any revenue?
+
No meaningful revenue. Cybin is pre-revenue and reported under $1 million in sales, so it operates at a loss while funding clinical trials, which is typical for a clinical-stage biotech.
What is HELP's lead drug candidate?
+
Its lead candidate is HLP003 (also called CYB003), a deuterated psilocybin analog being tested as an adjunctive treatment for major depressive disorder in the Phase 3 PARADIGM program that includes the APPROACH and EMBRACE studies.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell HELP; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.